WEP Clinical LTD (WEP), a specialist services company that works with pharmaceutical companies to help patients and physicians gain access to medicines when no other treatment options are available, has partnered with TaiMed Biologics to launch a Named Patient Program (NPP) for TROGARZO®, an IV treatment administered every two weeks for patients with multi-drug resistant HIV disease.  

The NPP is designed to ensure that physicians in Europe and other regions around the world, where TROGARZO® is not commercially available, can request TROGARZO® on behalf of individual patients who have trouble achieving viral suppression using standard HIV regimens.

Jas Khera, Managing Director of WEP Clinical, said:

“We are grateful to partner with TaiMed Biologics to help ensure broader access to this important HIV treatment option. The WEP Clinical team is looking forward to making TROGARZO® available to patients in Europe and rest of the world having a need for this specific HIV treatment.”

For full release and contact information please visit www.taimedbiologics.com